PPT-Imatinib

Resistance Geoffrey L Uy MD Associate Professor of Medicine Division of Oncology Natural History of CML Chronic Phase Accelerated Phase Blast Phase Duration 35 yrs untreated Varies. and. Breast Cancer Conference. CML . ASH Update. Michael J. Mauro, MD. CML Abstracts. Novel Agents. Abstract # 109. : . A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib or with the T315I Mutation. Definition of Gastrointestinal Stromal Tumor . the most common mesenchymal malignancy of (GI) tract. the diagnostic criteria for GIST remained controversial and somewhat confusing. Pathology Terms that Encompass the Spectrum of Gastrointestinal Stromal Tumors. Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof Clinical Oncology. Cairo University, Egypt. Introduction. CML is a . myeloproliferative. neoplasm characterized by presence of BCR-ABL fusion gene resulting in uncontrolled proliferation of mature and maturing granulocytes.. chromosomal positive acute lymphoblastic leukemia. Jiong. HU. Blood & Marrow Transplantation Center, . Rui. Jin Hospital, Shanghai Jiao Tong University School of Medicine. 1. Role of TKI: overview. stromal. tumors. Introduction. Tim Butler. March 8. th. , 2012. Topics for Today. GI . Stromal. Tumors (GIST). KIT Signaling. KIT targeted . therapy. ETV1. Interstitial Cells of . Cajal. Discovered by Ramon . Cara Peters. cpeters3@math.umd.edu. Advisor: Dr. . Doron. Levy. dlevy@math.umd.edu. Department of Mathematics. Center for Scientific Computing and Mathematical Modeling. Introduction. CML – cancer of the blood. Associate Professor . of Medicine. Division of Oncology. Natural History of CML. Chronic Phase. Accelerated Phase. Blast Phase. Duration. 3-5 . yrs. , untreated. Varies. Median. of months. Prognosis. Angela . Cioffi. , MD. Sarcoma Research Program coordinator. Mount Sinai Hospital, NY, USA. Istituto. . Europeo. . di. . Oncologia. , IRCSS, Milan, Italy. Today. ’. s job. Review some of the key studies sarcoma that dictate present management. BONJOUR. Tolerance of . Imatinib. . Dasatinib. . and . Nilotinib. . in the . treatment. . of . C. hronic . Myeloid Leukemia.. International Conférence on . Toxicogenomics. and Drug Monitoring and . I. ntroduction. CML is a clonal myeloproliferative neoplasm. Dysregulated production and uncontrolled proliferation of mature and maturing granulocyte with fairly normal differentiation. Fusion of 2 genes: BCR (or chromosome 22) and ABL1 (on chromosome 9), resulting in BCR-ABL1 fusion gene. Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof Clinical Oncology. Cairo University, Egypt. Introduction. CML is a . myeloproliferative. neoplasm characterized by presence of BCR-ABL fusion gene resulting in uncontrolled proliferation of mature and maturing granulocytes.. A FIP risk criteria 3 ears of imatinib (n= 31) 5 Y ears of imatinib (n= 20) p - value 2 0 1 (5.0 ) 0. 7 3a ) 3 (15 ) 3b 9 (29 ) ) 5 0 1 (5.0 ) 6a 11 (35 ) 6 (30 ) 6b 6 (19 ) 5 (25 ) Vpresented as nu Metastasis of DFSP is rare, occurring in approximately 1% to 4% of cases, but is a definite risk and it can contribute to mortality associated with uncontrolled disease. Clinical aspects Imatinib inh : . The Next Generation. Dr. Michael Heinrich, M.D. OHSU Knight Cancer Institute. Portland, OR. Background. Small molecule . kinase. inhibitors of KIT/PDGFRA such as imatinib and sunitinib have transformed the medical treatment of advanced GIST.